JP2024079713A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024079713A5 JP2024079713A5 JP2024038710A JP2024038710A JP2024079713A5 JP 2024079713 A5 JP2024079713 A5 JP 2024079713A5 JP 2024038710 A JP2024038710 A JP 2024038710A JP 2024038710 A JP2024038710 A JP 2024038710A JP 2024079713 A5 JP2024079713 A5 JP 2024079713A5
- Authority
- JP
- Japan
- Prior art keywords
- sarna
- seq
- conjugated
- sequence selected
- sense strand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562150889P | 2015-04-22 | 2015-04-22 | |
| US62/150,889 | 2015-04-22 | ||
| US201562235778P | 2015-10-01 | 2015-10-01 | |
| US62/235,778 | 2015-10-01 | ||
| US201662308521P | 2016-03-15 | 2016-03-15 | |
| US62/308,521 | 2016-03-15 | ||
| JP2020158141A JP6931733B2 (ja) | 2015-04-22 | 2020-09-23 | Ｃ／ＥＢＰアルファｓａＲＮＡ組成物および使用方法 |
| JP2021132267A JP2021192616A (ja) | 2015-04-22 | 2021-08-16 | Ｃ／ＥＢＰアルファｓａＲＮＡ組成物および使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021132267A Division JP2021192616A (ja) | 2015-04-22 | 2021-08-16 | Ｃ／ＥＢＰアルファｓａＲＮＡ組成物および使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024079713A JP2024079713A (ja) | 2024-06-11 |
| JP2024079713A5 true JP2024079713A5 (enExample) | 2024-10-10 |
Family
ID=55948895
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017554886A Active JP6768701B2 (ja) | 2015-04-22 | 2016-04-21 | Ｃ／ＥＢＰアルファｓａＲＮＡ組成物および使用方法 |
| JP2020158141A Active JP6931733B2 (ja) | 2015-04-22 | 2020-09-23 | Ｃ／ＥＢＰアルファｓａＲＮＡ組成物および使用方法 |
| JP2021132267A Pending JP2021192616A (ja) | 2015-04-22 | 2021-08-16 | Ｃ／ＥＢＰアルファｓａＲＮＡ組成物および使用方法 |
| JP2024038710A Pending JP2024079713A (ja) | 2015-04-22 | 2024-03-13 | Ｃ／ＥＢＰアルファｓａＲＮＡ組成物および使用方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017554886A Active JP6768701B2 (ja) | 2015-04-22 | 2016-04-21 | Ｃ／ＥＢＰアルファｓａＲＮＡ組成物および使用方法 |
| JP2020158141A Active JP6931733B2 (ja) | 2015-04-22 | 2020-09-23 | Ｃ／ＥＢＰアルファｓａＲＮＡ組成物および使用方法 |
| JP2021132267A Pending JP2021192616A (ja) | 2015-04-22 | 2021-08-16 | Ｃ／ＥＢＰアルファｓａＲＮＡ組成物および使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10912790B2 (enExample) |
| EP (1) | EP3286316A1 (enExample) |
| JP (4) | JP6768701B2 (enExample) |
| KR (2) | KR102599712B1 (enExample) |
| CN (2) | CN108291228A (enExample) |
| AU (3) | AU2016251415B9 (enExample) |
| SG (1) | SG11201707683YA (enExample) |
| WO (1) | WO2016170349A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3071696T1 (sl) * | 2013-11-22 | 2019-11-29 | Mina Therapeutics Ltd | C/EBP alfa kratko delujoči RNA sestavki in postopki uporabe |
| EP3551230A1 (en) * | 2016-12-08 | 2019-10-16 | CureVac AG | Rna for treatment or prophylaxis of a liver disease |
| WO2019048632A1 (en) | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | STABILIZED COMPOSITIONS OF SMALL ACTIVATORY RNA (PARNA) OF HNF4A AND METHODS OF USE |
| US20200208152A1 (en) * | 2017-09-08 | 2020-07-02 | Mina Therapeutics Limited | Stabilized sarna compositions and methods of use |
| CN108103108A (zh) * | 2018-01-30 | 2018-06-01 | 上海交通大学医学院附属瑞金医院 | Cebpa基因缺失斑马鱼突变体的制备及其应用 |
| US20210024928A1 (en) * | 2018-02-16 | 2021-01-28 | Mina Therapeutics Limited | C/ebp alpha sarna compositions and methods of use |
| US20210332366A1 (en) * | 2018-04-10 | 2021-10-28 | Ractigen Therapeutics | Novel Small Activating RNA |
| US20210254069A1 (en) | 2018-06-15 | 2021-08-19 | Mina Therapeutics Limited | Combination therapies comprising c/ebp alpha sarna |
| CN111849968A (zh) | 2019-04-30 | 2020-10-30 | 中美瑞康核酸技术(南通)研究院有限公司 | 寡核苷酸分子及其在急性间歇性卟啉症治疗中的应用 |
| JP2022542167A (ja) * | 2019-07-26 | 2022-09-29 | ミナ セラピューティクス リミテッド | Ｃ／ＥＢＰアルファｓａＲＮＡを使用する組成物および方法 |
| KR102892573B1 (ko) * | 2019-07-29 | 2025-12-01 | 브라이트씨드, 인크. | 소화기 건강의 개선 방법 |
| PE20220604A1 (es) * | 2019-09-20 | 2022-04-25 | Ractigen Therapeutics | Molecula de acido nucleico para el tratamiento de la trombocitopenia y uso de la misma |
| US20220404338A1 (en) * | 2019-12-03 | 2022-12-22 | Merck Sharp & Dohme Llc | In vitro cell based potency assay |
| IL299205A (en) * | 2020-07-17 | 2023-02-01 | Geron Corp | Subcutaneous telomerase inhibitor preparations and methods of using them |
| GB202019692D0 (en) * | 2020-12-14 | 2021-01-27 | Apterna Ltd | Aptamer-sirna fusions |
| WO2022147044A1 (en) | 2020-12-28 | 2022-07-07 | Gjerde Doulas T | Temperature stable nucleic acid method for preparing vaccine |
| US20240301409A1 (en) * | 2021-02-07 | 2024-09-12 | Ractigen Therapeutics | Chemically Modified Small Activating RNA |
| EP4329777A1 (en) | 2021-04-28 | 2024-03-06 | MiNA Therapeutics Limited | Combination therapies comprising c/ebp alpha sarna |
| KR102428121B1 (ko) * | 2021-10-20 | 2022-08-08 | 주식회사 네오나 | 변형된 rt-let7을 유효성분으로 포함하는 간암의 예방 또는 치료를 위한 딜리버리 시스템 |
| CN114306367B (zh) * | 2021-08-27 | 2023-03-28 | 赵小洋 | 一种含有C/EBPα-saRNA的组合物 |
| US12523658B2 (en) * | 2021-08-27 | 2026-01-13 | The Board Of Regents Of The University Of Texas System | Methods for the assessment of risk and treatments for liver cancers and lethal liver disease complications |
| EP4633618A1 (en) * | 2022-12-12 | 2025-10-22 | Regeneron Pharmaceuticals, Inc. | Treatment of type 2 diabetes and/or chronic kidney disease with hepatocyte nuclear factor 4 alpha (hnf4a) agonists |
| WO2024134199A1 (en) * | 2022-12-22 | 2024-06-27 | Mina Therapeutics Limited | Chemically modified sarna compositions and methods of use |
| WO2024165876A2 (en) * | 2023-02-10 | 2024-08-15 | Mina Therapeutics Limited | Compositions and methods of using c/ebp alpha sarna |
| WO2024175887A1 (en) | 2023-02-22 | 2024-08-29 | Mina Therapeutics Limited | Compositions and methods of using c/ebp alpha sarna |
| KR20240138691A (ko) * | 2023-03-13 | 2024-09-20 | 부산대학교 산학협력단 | 류마티스 관절염 진단용 바이오마커 조성물, 이를 이용한 진단용 키트 및 이를 이용한 류마티스 관절염 진단방법 |
| WO2025007024A1 (en) * | 2023-06-29 | 2025-01-02 | Repertoire Immune Medicines, Inc. | Lipid particles for delivering a payload |
| WO2025052098A1 (en) | 2023-09-08 | 2025-03-13 | Mina Therapeutics Limited | Tmem173 sarna compositions and methods of use |
| CN118480552B (zh) * | 2024-01-18 | 2024-10-01 | 成都先衍生物技术有限公司 | 一种靶向CEBPA基因表达的saRNA及其用途 |
| WO2025224036A1 (en) * | 2024-04-22 | 2025-10-30 | Mina Therapeutics Limited | Chemically modified sarna compositions and methods of use |
| WO2026027887A2 (en) | 2024-08-02 | 2026-02-05 | Mina Therapeutics Limited | Hbg1/2-sarna compositions and methods of use |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1791567B1 (en) * | 2004-08-10 | 2015-07-29 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
| EP2352849A1 (en) | 2008-11-13 | 2011-08-10 | Erasmus University Medical Center Rotterdam | Efficient detection of double mutants of the cebpa gene in acute myeloid leukemia |
| US8951981B2 (en) * | 2009-06-16 | 2015-02-10 | Curna, Inc. | Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1 |
| GB201010557D0 (en) | 2010-06-23 | 2010-08-11 | Mina Therapeutics Ltd | RNA molecules and uses thereof |
| CA2817256A1 (en) * | 2010-11-12 | 2012-05-18 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| KR102195514B1 (ko) | 2011-06-21 | 2020-12-29 | 미나 테라퓨틱스 리미티드 | 알부민 생산 및 세포 증식 |
| DE102011079572B4 (de) * | 2011-07-21 | 2024-12-05 | Endress+Hauser Conducta Gmbh+Co. Kg | Gradiometer zur Bestimmung der elektrischen Leitfähigkeit eines in einem Behältnis enthaltenen Mediums |
| JP2015536952A (ja) * | 2012-11-05 | 2015-12-24 | プロナイ セラピューティクス インコーポレイテッド | オリゴヌクレオチド癌療法の投薬および実施 |
| CA2890725A1 (en) * | 2012-11-05 | 2014-05-08 | Pronai Therapeutics, Inc. | Methods of using biomarkers for the treatment of cancer by modulation of bcl2|expression |
| WO2014078468A2 (en) * | 2012-11-15 | 2014-05-22 | Bristol-Myers Squibb Company | Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent |
| SI3071696T1 (sl) * | 2013-11-22 | 2019-11-29 | Mina Therapeutics Ltd | C/EBP alfa kratko delujoči RNA sestavki in postopki uporabe |
| US10758624B2 (en) * | 2015-07-02 | 2020-09-01 | City Of Hope | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof |
-
2016
- 2016-04-21 KR KR1020177030397A patent/KR102599712B1/ko active Active
- 2016-04-21 EP EP16721209.1A patent/EP3286316A1/en active Pending
- 2016-04-21 CN CN201680034224.1A patent/CN108291228A/zh active Pending
- 2016-04-21 AU AU2016251415A patent/AU2016251415B9/en active Active
- 2016-04-21 CN CN202210140475.5A patent/CN114525279A/zh active Pending
- 2016-04-21 US US15/568,139 patent/US10912790B2/en active Active
- 2016-04-21 WO PCT/GB2016/051117 patent/WO2016170349A1/en not_active Ceased
- 2016-04-21 JP JP2017554886A patent/JP6768701B2/ja active Active
- 2016-04-21 KR KR1020237037891A patent/KR102760315B1/ko active Active
- 2016-04-21 SG SG11201707683YA patent/SG11201707683YA/en unknown
-
2019
- 2019-07-31 AU AU2019210578A patent/AU2019210578B2/en active Active
-
2020
- 2020-09-23 JP JP2020158141A patent/JP6931733B2/ja active Active
- 2020-12-09 US US17/117,025 patent/US20210187007A1/en not_active Abandoned
-
2021
- 2021-08-16 JP JP2021132267A patent/JP2021192616A/ja active Pending
-
2022
- 2022-04-08 AU AU2022202355A patent/AU2022202355A1/en not_active Abandoned
-
2024
- 2024-03-13 JP JP2024038710A patent/JP2024079713A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024079713A5 (enExample) | ||
| JP2020188756A5 (enExample) | ||
| JP2023068035A5 (enExample) | ||
| Altenburg et al. | Immunomodulatory effects of macrolide antibiotics–part 1: biological mechanisms | |
| JP2023536974A5 (enExample) | ||
| JP2009530319A5 (enExample) | ||
| JP2016518331A5 (enExample) | ||
| JP2022506503A5 (enExample) | ||
| JP2021521796A5 (enExample) | ||
| JP2021520207A5 (enExample) | ||
| Mellbye et al. | Variations in amino acid composition of antisense peptide-phosphorodiamidate morpholino oligomer affect potency against Escherichia coli in vitro and in vivo | |
| JP2013535212A5 (enExample) | ||
| DE50214266D1 (de) | Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung | |
| JP2009513144A5 (enExample) | ||
| JP2018512155A5 (enExample) | ||
| JP2023538284A5 (enExample) | ||
| JP2013511990A5 (enExample) | ||
| RU2014125496A (ru) | Комбинированная терапия для лечения нарушений слуха и равновесия | |
| JP2015532097A5 (enExample) | ||
| JP2015128433A5 (enExample) | ||
| WO2012174224A2 (en) | Methods for administering nucleic acid-based therapeutics | |
| JP2003219893A5 (enExample) | ||
| JP2018088923A (ja) | 線維症予防又は治療剤 | |
| AU2009311748B2 (en) | Compounds and methods for reducing the recruitment and/or migration of polymorphonuclear cells | |
| JP2022550979A5 (enExample) |